Cargando…

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

Detalles Bibliográficos
Autores principales:	Rhodes, Joanna, Shadman, Mazyar, Lamanna, Nicole, S. Manzoor, Beenish, Coombs, Catherine, Ghosh, Nilanjan, H. Tuncer, Hande, Emechebe, Dozie, R. Brown, Jennifer, Alhasani, Hasan, Leslie, Lori, Roeker, Lindsey, Ujjani, Chaitra, Eichhorst, Barbara, Fleury, Isabelle, Skarbnik, Alan, T. Hill, Brian, Lansigan, Frederick, M. Barr, Paul, Davids, Matthew, Fox, Christopher, Choi, Yun, E. Jensen, Christopher, Schuh, Anna, Kennard, Kaitlin, Jawaid, Dureshahwar, Pivneva, Irina, Watson, Talissa, Eyre, Toby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429228/ http://dx.doi.org/10.1097/01.HS9.0000969492.96103.aa

Ejemplares similares

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
por: Lansigan, Frederick, et al.
Publicado: (2023)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021)

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up
por: Ujjani, Chaitra S., et al.
Publicado: (2022)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
por: Karr, Matthew, et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
por: Fürstenau, Moritz, et al.
Publicado: (2019)

CCNP security VPN 642-647 quick reference
por: Matei, Cristian
Publicado: (2011)

The role of Cysteine 6.47 in class A GPCRs
por: Olivella, Mireia, et al.
Publicado: (2013)

647. Diagnoses Associated with Temperature ≥104°F in Adults
por: Chi, Sharon, et al.
Publicado: (2019)

CCNP security VPN 642-647 official cert guide
por: Hooper, Howard
Publicado: (2012)

Withdrawn Paper: Molecules 2001, 6, 647-654 [1]
Publicado: (2003)

Role of miR-647 in human gastric cancer suppression
por: Cao, Wenlong, et al.
Publicado: (2017)

Spotlight on the Expanding Role of miR-647 in Human Cancers
por: Jalili, Mohammadmahdi, et al.
Publicado: (2023)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
por: Shadman, Mazyar, et al.
Publicado: (2023)

Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
por: Babb, Rachelle, et al.
Publicado: (2018)

MON-647 Mechanisms of Insulin Resistance in Skeletal Muscle in Women with PCOS
por: Moreno-Asso, Alba, et al.
Publicado: (2020)

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
por: Mato, Anthony R., et al.
Publicado: (2022)

Primary effusion lymphoma: current perspectives
por: Narkhede, Mayur, et al.
Publicado: (2018)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Phosphorylation of the Actin Binding Protein Drebrin at S647 Is Regulated by Neuronal Activity and PTEN
por: Kreis, Patricia, et al.
Publicado: (2013)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
por: Liang, Emily, et al.
Publicado: (2023)

MCITP Windows Server 2008 Enterprise Administrator Study Guide: (Exam 70-647)
por: Johnson, Steven
Publicado: (2008)

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories
por: Sfeir, Maroun M
Publicado: (2020)

PPR647 Protein Is Required for Chloroplast RNA Editing, Splicing and Chloroplast Development in Maize
por: Zhao, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_snan7ogo4cvgeqscuo8v8he6nr